A new draft guidance document released by the US Food and Drug Administration (FDA) instructs industry on the nonclinical evidence needed to identify potentially harmful effects of an investigational ...
Revvity, Inc. RVTY recently announced that its subsidiary, Immunodiagnostic Systems (“IDS”), received FDA clearance for its Total Testosterone automated chemiluminescence immunoassay (ChLIA). The ...